Pancreatic Disorders Clinical Trials

A listing of Pancreatic Disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 25 clinical trials
Featured trial
RTOG 0848: A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.

RTOG 0848: A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.

  • 639 views
  • 08 Nov, 2020
  • 1 location
Featured trial
Prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy

Prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy

  • 114 views
  • 08 Nov, 2020
  • 1 location
The Cancer of the Pancreas Screening-5 CAPS5)Study (CAPS5)

Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.

BRCA2
pancreatitis
synthetic secretin
BRCA1
cancer
  • 185 views
  • 21 Jul, 2022
  • 8 locations
Custodiol-N Solution Compared With Custodiol Solution in Organ Transplantation (Kidney, Liver and Pancreas)

(kidney, liver and pancreas) Protocol number: CL-N-KLP-TX-III/07-AT/17 Trial design The study design is a prospective, randomized, single blind, multicentre, phase III comparison study of

kidney transplant
organ transplantation
  • 9 views
  • 07 Feb, 2022
  • 1 location
Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer

The prognosis of pancreatic cancer is extremely poor. Current guidelines recommend FOLFIRINOX or modified-FOLFIRINOX as the first-line chemotherapeutic regimen. Studies have shown that immunotherapy with Anti-PD-1 antibody can effectively increase the response rate and prolong patient survival in a number of cancer diseases. Here investigators intend to compare the therapeutic …

pancreatic ductal adenocarcinoma
breast ductal carcinoma
metastasis
obstruction
adenocarcinoma
  • 32 views
  • 09 Feb, 2022
  • 1 location
A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

The purpose of this study is to evaluate the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who are homozygous for F508del, heterozygous for F508del and a gating (F/G) or residual function (F/RF) mutation, or have at least 1 other TCR CF transmembrane conductance regulator (CFTR) gene mutation and …

cftr gene
tezacaftor
fibrosis
forced expiratory volume
  • 4 views
  • 28 Jul, 2022
  • 140 locations
A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

The purpose of this study is to evaluate the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who are heterozygous for F508del and a minimal function mutation (F/MF participants).

tezacaftor
fibrosis
forced expiratory volume
  • 0 views
  • 11 Aug, 2022
  • 122 locations
Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

This study will evaluate the efficacy, pharmacodynamics (PD) and safety of ELX/TEZ/IVA in participants 6 years of age and older with a non-F508del ELX/TEZ/IVA-responsive cystic fibrosis transmembrane conductance regulator gene (CFTR) mutation.

elexacaftor
fibrosis
forced expiratory volume
tezacaftor
ivacaftor
  • 0 views
  • 10 Aug, 2022
  • 28 locations
Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

Brief Summary: The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for front line treatment of locally-advanced pancreatic adenocarcinoma.The device is an experimental, portable, battery operated device for chronic administration of …

cancer
advanced pancreatic adenocarcinoma
metastasis
gemcitabine
paclitaxel
  • 440 views
  • 11 Aug, 2022
  • 116 locations
18F-DOPA II - PET Imaging Optimization

A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations: Pediatric patients (less than 18 years old) with congenital hyperinsulinism. Pediatric patients (less than 18 years old) with neuroblastoma. Pediatric (less than 18 years old) or Adult patients (18 or older) with …

dementia
dopa
parkinson's disease
  • 8 views
  • 03 May, 2022
  • 1 location